Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma Journal Article


Authors: Rizk, N. P.; Servais, E. L.; Tang, L. H.; Sima, C. S.; Gerdes, H.; Fleisher, M.; Rusch, V. W.; Adusumilli, P. S.
Article Title: Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma
Abstract: Background: Mesothelin is overexpressed in several malignancies and is purportedly a specific marker of malignant transformation. In this pilot study, we investigated whether tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's esophagus (BE) and in esophageal adenocarcinoma (EAC). Methods: Mesothelin expression was retrospectively evaluated in normal, BE, and EAC tissue from surgically resected esophageal specimens (n = 125). In addition, soluble mesothelin-related peptide (SMRP) levels were measured in serum. Results: Normal esophageal mucosa did not express mesothelin. BE tissue with high-grade dysplasia specifically expressed mesothelin, whereas BE tissue with low-grade or without dysplasia did not. Fifty-seven (46%) EAC tumors were positive for mesothelin. EAC tumors with BE expressed mesothelin more often than those without BE (58% vs. 35%, P = 0.01). SMRP levels were elevated in 70% of EAC patients (mean = 0.89 nmol/L; range: 0.03-3.77 nmol/L), but not in patients with acid reflux and/or BE. Conclusions: Mesothelin is commonly expressed in BE-associated EAC. On the basis of this pilot study, a prospective study is under way to evaluate tissue and serum mesothelin which are potential markers of neoplastic progression in BE and in EAC (NCT01393483). Impact: Current surveillance methods in Barrett's esophagus are invasive and neither cost-effective nor sensitive. This pilot study suggests that serum mesothelin is a marker of neoplastic transformation in BE and may provide a noninvasive method to improve identification of malignant transformation. ©2012 AACR.
Journal Title: Cancer Epidemiology Biomarkers and Prevention
Volume: 21
Issue: 3
ISSN: 1055-9965
Publisher: American Association for Cancer Research  
Date Published: 2012-03-01
Start Page: 482
End Page: 486
Language: English
DOI: 10.1158/1055-9965.epi-11-0993
PROVIDER: scopus
PMCID: PMC3297720
PUBMED: 22237988
DOI/URL:
Notes: --- - "Export Date: 1 May 2012" - "CODEN: CEBPE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Camelia S Sima
    212 Sima
  2. Hans Gerdes
    176 Gerdes
  3. Valerie W Rusch
    864 Rusch
  4. Nabil Rizk
    139 Rizk
  5. Elliot Louis Servais
    17 Servais
  6. Laura Hong Tang
    447 Tang
  7. Martin Fleisher
    312 Fleisher